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CORRESPONDENCE

Letter to the Editor: Successful treatment of multidrug
resistant hepatitis C after >12 months of continuous
therapy with direct-acting antivirals
To the editor, In the era of highly effective direct-acting
antiviral (DAA) therapies for chronic hepatitis C virus
(HCV) infection, the <5% of patients who experience
treatment failure represent a clinical challenge. Current
guidelines recommend a 16-week course of treatment
with glecaprevir (GLE)/pibrentasvir (PIB) plus sofosbuvir
(SOF) and ribavirin (RBV) for patients who are multidrug
resistant and otherwise difficult to treat.[1] There are no
clinical data to support treatment decisions for patients
who fail this last line of therapy. We present the case
of a patient with a history of multiple failed treatments
who ultimately achieved sustained virological response
(SVR) after an extended course of DAA regimens.

BACKG ROUND
A 71-year-old man with HCV genotype (GT) 1a and cirrhosis had previously failed treatments that included
pegylated interferon (IFN), 24 weeks of SOF/ledipasvir,
12 weeks of GLE/PIB with RBV (MAGELLAN-2 trial)[2],
16 weeks of GLE/PIB/RBV plus SOF (MAGELLAN-3;
the only one of 23 trial participants to not achieve
SVR)[2], and 12 weeks of SOF/velpatasvir (VEL)/voxilaprevir with RBV. The patient was adherent with all
treatments. Testing for resistance-
associated substitutions (RAS) during the MAGELLAN-2 and -3 trials
detected relevant changes in both NS3 (A156V) and
NS5A (Q30K and Y93H) regions (as detailed in Wyles
et al.[2]).

E X TENDED TR E ATM ENT
Failure to respond to multiple DAA salvage regimens
led to the decision to initiate a long-term course of antivirals with the goals of prolonged viral suppression and
symptom reduction. Figure 1 illustrates the type and
duration of treatments provided; insurance limitations,
and patient cost concerns necessitated the use of several different regimens, including those made available
through the generosity of a private donor.
As shown, treatment began with an 8-week course
of SOF/daclatasvir+RBV and IFN. During this course
of therapy, the patient contracted COVID-
19; RBV
and IFN were paused for 2 weeks because of patient
fatigue, then restarted and maintained (as tolerated)
throughout the following treatment regimens. At week
4 post-treatment initiation, the patient had an undetectable viral RNA level; tests repeated at 2–4 -week intervals for the duration of treatment remained negative.
At week 12, the regimen was changed to SOF/VEL.
At week 17, we initiated an extended (26-week) course
of GLE/PIB; 13 weeks into this course (week 30 overall), SOF was added to the regimen. This combined
GLE/PIB/SOV regimen was continued for 13 weeks.
Finally, at week 43, treatment reverted to SOF/VEL for
13 weeks. All treatment ended at week 56.
The patient underwent follow-up HCV RNA testing
at 6, 13, and 24 weeks after completion of treatment.
Levels remained “undetectable,” fulfilling criteria for
SVR24.

F I G U R E 1 Timeline of treatment and hepatitis C virus (HCV) RNA testing. DAC, daclatasvir; GLE, glecaprevir; IFN, pegylated
interferon; PIB, pibrentasvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.
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D I SCUSS I O N
We present what we believe is the first case description of SVR24 in a patient with multiple NS3 and NS5A
RASs, coupled with a history of both on-treatment viral
breakthrough and post-treatment relapse across multiple extended courses of the currently recommended
salvage DAA regimens. The goal of long-
term viral
suppression in order to ultimately achieve SVR may
represent a viable option for these rare patients with
intractable HCV infections.
Treatment guidelines for patients with treatment-
resistant infections are based largely on limited case
series or anecdotal reports, as there are too few patients available to support additional clinical trials. Given
that our patient had failed multiple extended courses
of currently recommended therapies for re-treatment
after DAA treatment failure, there was a complete absence of evidence-based options to guide treatment
selection. Our goal, based on clinical judgment, was
to achieve long-term viral suppression even if this required that the patient remain on-treatment indefinitely.
To achieve this aim, insurance and financial constraints necessitated—
perhaps fortuitously—
the use
of multiple different regimens. Previous testing in our
patient detected RASs that are strongly associated
with resistance to GLE/PIB in GT1a infections.[3] We
initiated treatment with two SOF-based regimens and
achieved undetectable viral loads before transitioning
to GLE/PIB. The patient also took pegylated IFN and
RBV intermittently for the entire duration of treatment.
Although there is evidence that adjuvant RBV increases
the rate of SVR after DAA treatment failure,[4] the potential beneficial role of IFN can only be speculated
upon. It is also possible that some refractory cases of
HCV may simply require a considerably longer span of
treatment to successfully eliminate the virus.
Our patient—despite a history of failing to achieve
SVR across both IFN and multiple DAA regimens—was
finally able to achieve SVR24 after roughly 13 months
of continuous DAA treatment coupled with RBV and
IFN as tolerated. It is possible, therefore, that extending treatment length beyond current recommendations
may be necessary to successfully induce a durable response among patients with multiple RASs and previous treatment failures.
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